• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Unresolved questions in hormonal therapy for prostate cancer].

作者信息

Oishi K

机构信息

Dept. of Urology, Kyoto University.

出版信息

Gan To Kagaku Ryoho. 1994 Sep;21(12):1928-33.

PMID:8085843
Abstract

Although there still are unresolved questions in hormonal therapy for prostatic cancer patients, it has long been considered one of the major therapeutic modalities after the report by Dr. Huggins in 1941. The unresolved questions are: "Can hormonal therapy for prostatic cancer prolong the survival of the patients?" "Can hormonal therapy improve the quality of life of prostatic cancer patients?" "Is complete androgen blockade superior to androgen reduction therapy?" "Is pre-operative hormonal therapy more beneficial than post-operative hormonal therapy?" and "How do we handle relapsed prostatic cancer?" We, urologists, unanimously recognize the beneficial effects of hormonal therapy in most prostatic cancer patients, even in a rather short span. Furthermore, other therapeutic modalities, except radical prostatectomy or radical radiation, can not eradicate cancer cells from patients. We can not treat prostatic cancer patients leading to better outcomes without hormonal therapy. Thus, hormonal therapy is chosen in most of the prostatic cancer patients as a first line therapy. Each type of hormonal therapy for prostatic cancer has specific characteristics, with advantages and disadvantages. We must choose the best hormonal therapy in terms of cost-benefit and quality of life during the therapy.

摘要

相似文献

1
[Unresolved questions in hormonal therapy for prostate cancer].
Gan To Kagaku Ryoho. 1994 Sep;21(12):1928-33.
2
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).雄激素剥夺疗法作为局限性前列腺癌的主要治疗方法:来自前列腺癌战略泌尿学研究计划(CaPSURE)的数据。
Cancer. 2006 Apr 15;106(8):1708-14. doi: 10.1002/cncr.21799.
3
Hormonal therapy for locally advanced prostate cancer.局部晚期前列腺癌的激素治疗
NCI Monogr. 1988(7):171-4.
4
Endocrine treatment of prostate cancer.前列腺癌的内分泌治疗
J Steroid Biochem Mol Biol. 2004 Nov;92(4):287-95. doi: 10.1016/j.jsbmb.2004.10.005. Epub 2004 Dec 31.
5
[First line therapy in the treatment of metastatic prostate cancer].[转移性前列腺癌治疗中的一线治疗]
Gan To Kagaku Ryoho. 2003 Jan;30(1):43-9.
6
[Hormone therapy for prostate cancer].[前列腺癌的激素治疗]
Bull Cancer. 2004 Jan;91(1):69-74.
7
[Management of a hormone dependent cancer with endocrine therapy--prostate cancer].[内分泌治疗激素依赖性癌症——前列腺癌的管理]
Gan To Kagaku Ryoho. 2001 Jul;28(7):917-26.
8
Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.初始最大雄激素阻断治疗后复发的晚期前列腺癌的替代性非甾体抗雄激素治疗
J Urol. 2008 Sep;180(3):921-7. doi: 10.1016/j.juro.2008.05.045. Epub 2008 Jul 17.
9
Advanced prostatic carcinoma. Early versus late endocrine therapy.
Urol Clin North Am. 1991 Feb;18(1):15-24.
10
[Radiotherapy combined with hormonal therapy as treatment method in patients with prostate cancer: still more questions than answers].[放射治疗联合激素治疗作为前列腺癌患者的治疗方法:问题仍多于答案]
Przegl Lek. 2005;62(12):1455-9.